RU2018112720A - Производные пантотената для лечения неврологических заболеваний - Google Patents
Производные пантотената для лечения неврологических заболеваний Download PDFInfo
- Publication number
- RU2018112720A RU2018112720A RU2018112720A RU2018112720A RU2018112720A RU 2018112720 A RU2018112720 A RU 2018112720A RU 2018112720 A RU2018112720 A RU 2018112720A RU 2018112720 A RU2018112720 A RU 2018112720A RU 2018112720 A RU2018112720 A RU 2018112720A
- Authority
- RU
- Russia
- Prior art keywords
- subject
- compound according
- compound
- administering
- effective amount
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/24—Esteramides
- C07F9/2404—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic
- C07F9/242—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic of hydroxyaryl compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/222—Amides of phosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/24—Esteramides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/24—Esteramides
- C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
- C07F9/2458—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
- C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261639602P | 2012-04-27 | 2012-04-27 | |
| US61/639,602 | 2012-04-27 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014147739A Division RU2653497C2 (ru) | 2012-04-27 | 2013-04-26 | Производные пантотената для лечения неврологических заболеваний |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2018112720A true RU2018112720A (ru) | 2019-02-28 |
Family
ID=48428654
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018112720A RU2018112720A (ru) | 2012-04-27 | 2013-04-26 | Производные пантотената для лечения неврологических заболеваний |
| RU2014147739A RU2653497C2 (ru) | 2012-04-27 | 2013-04-26 | Производные пантотената для лечения неврологических заболеваний |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014147739A RU2653497C2 (ru) | 2012-04-27 | 2013-04-26 | Производные пантотената для лечения неврологических заболеваний |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US8673883B2 (enExample) |
| EP (3) | EP3489248A1 (enExample) |
| JP (3) | JP6254151B2 (enExample) |
| KR (1) | KR20150035550A (enExample) |
| CN (2) | CN106977544B (enExample) |
| AU (3) | AU2013251345B2 (enExample) |
| BR (1) | BR112014026817A2 (enExample) |
| CA (1) | CA2879314A1 (enExample) |
| CY (2) | CY1118198T1 (enExample) |
| DK (2) | DK2841438T3 (enExample) |
| ES (2) | ES2600179T3 (enExample) |
| HR (2) | HRP20161389T1 (enExample) |
| HU (2) | HUE042199T2 (enExample) |
| IN (1) | IN2014DN09584A (enExample) |
| LT (2) | LT2841438T (enExample) |
| MX (1) | MX360149B (enExample) |
| PL (2) | PL2841438T3 (enExample) |
| PT (2) | PT3112372T (enExample) |
| RS (2) | RS58336B1 (enExample) |
| RU (2) | RU2018112720A (enExample) |
| SI (2) | SI3112372T1 (enExample) |
| SM (2) | SMT201900007T1 (enExample) |
| TR (1) | TR201819263T4 (enExample) |
| WO (1) | WO2013163576A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE042199T2 (hu) * | 2012-04-27 | 2019-06-28 | Retrophin Inc | Pantotenát-származékok neurológiai rendellenességek kezelésére |
| WO2015061792A1 (en) | 2013-10-25 | 2015-04-30 | Retrophin, Inc. | Panothenate derivatives for the treatment of neurological disorders |
| EP2868662A1 (en) * | 2013-11-04 | 2015-05-06 | Acies Bio d.o.o. | Stable pantetheine derivatives for the treatment of pantothenate kinase associated neurodegeneration (pkan) and methods for the synthesis of such compounds |
| CA3007063A1 (en) * | 2015-12-08 | 2017-06-15 | Retrophin, Inc. | Cyclic phosphates and cyclic phosphoramidates for the treatment of neurologic disorders |
| US20200121604A1 (en) * | 2017-02-07 | 2020-04-23 | Retrophin, Inc. | Solid fosmetpantotenate formulations |
| US11746087B1 (en) | 2022-03-18 | 2023-09-05 | Enveric Biosciences Canada Inc. | C4-carboxylic acid-substituted tryptamine derivatives and methods of using |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2676976A (en) | 1950-12-04 | 1954-04-27 | Nat Res Dev | Synthesis of pantothenic acid-4' phosphate |
| US2870188A (en) | 1955-10-03 | 1959-01-20 | Hoffmann La Roche | Process for the manufacture of pantothenic acid 4'-phosphate and its salts |
| RU2002110463A (ru) * | 1999-09-21 | 2004-02-27 | Басф Акциенгезелльшафт (De) | Способ и микроорганизмы для получения пантосоединений |
| WO2003008626A2 (en) | 2001-07-20 | 2003-01-30 | Oregon Health And Science University | Novel human nucleic acids encoding a pantothenate kinase and methods of use |
| EP1520030B1 (en) * | 2002-07-03 | 2011-10-26 | Basf Se | Microorganisms and processes for enhanced production of pantothenate |
| CA2618335C (en) | 2005-08-15 | 2015-03-31 | F.Hoffmann-La Roche Ag | Antiviral phosphoramidates of 4'-substituted pronucleotides |
| HUE042199T2 (hu) * | 2012-04-27 | 2019-06-28 | Retrophin Inc | Pantotenát-származékok neurológiai rendellenességek kezelésére |
-
2013
- 2013-04-26 HU HUE16001739A patent/HUE042199T2/hu unknown
- 2013-04-26 AU AU2013251345A patent/AU2013251345B2/en not_active Ceased
- 2013-04-26 LT LTEP13722201.4T patent/LT2841438T/lt unknown
- 2013-04-26 RU RU2018112720A patent/RU2018112720A/ru not_active Application Discontinuation
- 2013-04-26 WO PCT/US2013/038458 patent/WO2013163576A1/en not_active Ceased
- 2013-04-26 BR BR112014026817A patent/BR112014026817A2/pt not_active Application Discontinuation
- 2013-04-26 US US13/871,691 patent/US8673883B2/en not_active Expired - Fee Related
- 2013-04-26 TR TR2018/19263T patent/TR201819263T4/tr unknown
- 2013-04-26 RU RU2014147739A patent/RU2653497C2/ru not_active IP Right Cessation
- 2013-04-26 CN CN201611221824.7A patent/CN106977544B/zh not_active Expired - Fee Related
- 2013-04-26 MX MX2014013048A patent/MX360149B/es active IP Right Grant
- 2013-04-26 PT PT16001739T patent/PT3112372T/pt unknown
- 2013-04-26 SI SI201331263T patent/SI3112372T1/sl unknown
- 2013-04-26 EP EP18201414.2A patent/EP3489248A1/en not_active Withdrawn
- 2013-04-26 RS RS20190049A patent/RS58336B1/sr unknown
- 2013-04-26 KR KR20147033141A patent/KR20150035550A/ko not_active Abandoned
- 2013-04-26 CN CN201380033271.0A patent/CN104520307B/zh not_active Expired - Fee Related
- 2013-04-26 HU HUE13722201A patent/HUE029474T2/en unknown
- 2013-04-26 LT LTEP16001739.8T patent/LT3112372T/lt unknown
- 2013-04-26 CA CA2879314A patent/CA2879314A1/en not_active Abandoned
- 2013-04-26 JP JP2015509192A patent/JP6254151B2/ja not_active Expired - Fee Related
- 2013-04-26 DK DK13722201.4T patent/DK2841438T3/en active
- 2013-04-26 HR HRP20161389TT patent/HRP20161389T1/hr unknown
- 2013-04-26 IN IN9584DEN2014 patent/IN2014DN09584A/en unknown
- 2013-04-26 EP EP16001739.8A patent/EP3112372B1/en active Active
- 2013-04-26 SM SM20190007T patent/SMT201900007T1/it unknown
- 2013-04-26 RS RS20160939A patent/RS55319B1/sr unknown
- 2013-04-26 SI SI201330307A patent/SI2841438T1/sl unknown
- 2013-04-26 ES ES13722201.4T patent/ES2600179T3/es active Active
- 2013-04-26 PL PL13722201T patent/PL2841438T3/pl unknown
- 2013-04-26 ES ES16001739T patent/ES2708813T3/es active Active
- 2013-04-26 DK DK16001739.8T patent/DK3112372T3/en active
- 2013-04-26 EP EP13722201.4A patent/EP2841438B1/en active Active
- 2013-04-26 PT PT137222014T patent/PT2841438T/pt unknown
- 2013-04-26 PL PL16001739T patent/PL3112372T3/pl unknown
-
2014
- 2014-01-16 US US14/157,173 patent/US9181286B2/en not_active Expired - Fee Related
-
2015
- 2015-09-30 US US14/871,450 patent/US9629862B2/en not_active Expired - Fee Related
-
2016
- 2016-11-03 SM SM201600395T patent/SMT201600395B/it unknown
- 2016-11-04 CY CY20161101130T patent/CY1118198T1/el unknown
-
2017
- 2017-03-22 JP JP2017055792A patent/JP6560284B2/ja not_active Expired - Fee Related
- 2017-10-04 AU AU2017239508A patent/AU2017239508C1/en not_active Ceased
-
2019
- 2019-01-04 HR HRP20190038TT patent/HRP20190038T1/hr unknown
- 2019-02-05 CY CY20191100156T patent/CY1121238T1/el unknown
- 2019-07-18 JP JP2019132651A patent/JP2019206553A/ja active Pending
- 2019-08-20 AU AU2019219733A patent/AU2019219733A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018112720A (ru) | Производные пантотената для лечения неврологических заболеваний | |
| Chonpathompikunlert et al. | Piperine, the main alkaloid of Thai black pepper, protects against neurodegeneration and cognitive impairment in animal model of cognitive deficit like condition of Alzheimer’s disease | |
| CN101137639B (zh) | 类黄酮化合物及其用途 | |
| CN101437510B (zh) | 用作乙酰胆碱酯酶抑制剂的药物组合物 | |
| BR112015028501B8 (pt) | Compostos derivados de bipirazol, seus sais, composição compreendendo o composto ou o sal, método de inibição in vitro de uma atividade de jak1, e processo de preparação de sal de ácido fosfórico | |
| EA201390971A1 (ru) | ИМИДАЗО[5,1-f][1,2,4]ТРИАЗИНЫ ДЛЯ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ РАССТРОЙСТВ | |
| CN109069508A (zh) | Ezh2抑制剂及其用途 | |
| KR20140009244A (ko) | 통증 치료용 화합물 및 방법 | |
| BR112012015714A2 (pt) | composto, composição farmacêutica, método para o tratamento de uma doença neurodegenerativa, método para reduzir a concentração de p-ser-alfa-sinucleina em tecido cerebral, e, método para o tratamento de um câncer | |
| KR20150081422A (ko) | mTOR 경로 관련 질병 치료를 위한 화합물 | |
| Jebasingh et al. | The protective effects of Cyperus rotundus on behavior and cognitive function in a rat model of hypoxia injury | |
| FI3347002T3 (fi) | Alzheimerin taudin hoitaminen tietyssä potilaspopulaatiossa | |
| JP2015515496A5 (enExample) | ||
| IN2014CN03111A (enExample) | ||
| AR046318A1 (es) | Sales de tiotropio, procedimientos para su preparacion y composiciones farmaceuticas que las contienen. | |
| JP2023503769A (ja) | 固形腫瘍の処置のための組成物 | |
| CA3129749A1 (en) | Compositions and methods relating to use of agonists of alpha5-containing gabaa receptors | |
| KR101349113B1 (ko) | 노루궁뎅이 버섯에서 추출된 특정물질을 유효성분으로 포함하는 치매 예방 또는 치료용 약제학적 조성물 및 그 제조방법 | |
| ES2843511T3 (es) | Métodos para reducir las concentraciones en sangre de triglicéridos, colesterol total y lipoproteínas de baja densidad | |
| US20230355584A1 (en) | Compositions and methods for the treatment of lipid-related disorders | |
| US20240041827A1 (en) | Compositions for the treatment of fat related conditions and disorders | |
| RU2007112950A (ru) | Новые производные 3,5-секо-4-норхолестана и их применение | |
| Ahmadi et al. | Substituted Aminobenzothiazole derivatives of Tacrine: synthesis and study on learning and memory impairment in scopolamine-induced model of amnesia in rat | |
| CN101355948A (zh) | 用于治疗增殖性疾病的Roscovitine和HDAC抑制剂的组合 | |
| CN104622874A (zh) | Ccr4拮抗剂在抑制癌生长及转移中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20160427 |